93 results about "Recurrent anxiety" patented technology

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

In alternative embodiments, provided are products of manufacture, including devices and integrated systems, and methods, for reducing error-related negativity (ERN) and anxiety, and for treating or ameliorating Anxiety Disorders such as Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD) and obsessive-compulsive disorder (OCD).

This invention regarding touch therapy has been around for centuries, and continues to evolve into various models and styles. This therapy has been practiced by various groups and is believed to reduce muscle pain, relieve stress, and provide relaxation. One touch therapy that is part of sensory integration is deep touch pressure therapy. By applying deep pressure to the body of an individual experiencing anxiety disorders, the body will feel embraced and the user will feel calmer. Current deep touch pressure therapy devices still have limitations in mobility and flexibility, so further design studies are needed to support the invention of flexible therapy devices. This invention is a vest-shaped therapy device that uses a strap tightening mechanism to provide a pressure sensation to the user.The simple shape of the vest can be a solution to the need for a therapy tool that is easy to carry and apply.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The present invention discloses a compound of formula (I); specifically, the invention relates to a compound shown as a formula (I) or pharmaceutically acceptable salt, stereoisomer, prodrug, deuterated derivative or solvate, and application of the compounds in drugs for treating or preventing pain, gout, epilepsy, insomnia, anxiety disorder, depression, Parkinson's syndrome and other related diseases.

The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).

The invention belongs to the technical field of nerve drugs, and particularly relates to application of an orexin receptor 1 antagonist and / or an orexin receptor 2 antagonist in preparation of drugs for treating insomnia or anxiety, and the compound is a compound and salt shown in the following structure. In in-vivo experiments, the traditional Chinese medicine composition shows a more excellent anti-insomnia effect and shows a good anti-anxiety effect. In addition, the structure also has better stability and pharmacokinetic characteristics, such as higher exposure and half-life period.

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

Provided are a polypeptide and a use thereof. Provided is a use of a polypeptide in preparation of a medication for treating and / or preventing PTSD, depression, or anxiety disorder, thereby providing a treatment strategy for PTSD, depression, or anxiety disorder. Provided are a polypeptide, a complex, a nucleic acid molecule, an expression vector, and a host cell.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The application discloses an anxiety disorder detection system based on hierarchical cross-modal attention fusion, applied to the technical field of anxiety disorder detection, comprising: a modal feature coding module: based on a pre-trained BERT model, global semantic features of patient text are extracted; through a stacked double-layer bidirectional long short-term memory network, time sequence dynamic characteristics and context-dependent information of patient audio features are captured; based on a deep convolutional neural network, deep video features of patient speech video are extracted; a hierarchical cross-modal attention fusion module: based on a hierarchical bidirectional attention fusion strategy, bidirectional attention interaction fusion of text and audio modal features and bidirectional attention interaction fusion of fusion results and video modal features are carried out respectively; a residual enhancement multilayer perceptron classification decision module: multichannel fusion features are input to a residual enhancement structure-based multilayer perceptron classification decision model, and an anxiety disorder detection result is obtained. The application effectively improves the anxiety disorder detection precision.

Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT2AR.

The present application relates to the technical field of neuropharmacology and psychiatry, and discloses a nasal drug composition, which comprises a therapeutically effective dose of a 5-HT1D receptor antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable cyclodextrin or a derivative thereof; the composition is a nasal preparation, and after nasal administration, the elimination half-life of the 5-HT1D receptor antagonist in brain tissue is longer than that in plasma, or the 5-HT1D receptor antagonist is preferentially retained in brain tissue. The present application combines the 5-HT1D receptor antagonist, the specific cyclodextrin inclusion technology and the nasal administration route, only makes the poorly soluble CNI3176 into a high-concentration (such as 1 mg / mL) clear solution, significantly improves the physical and chemical stability of the preparation, and enables the drug to reach the brain target in a few minutes (Tmax≤0.1 h), thereby providing a new type of anti-anxiety treatment solution which is rapid in effect, significant in curative effect, low in side effect risk and possible to avoid tolerance.

The invention provides a Chinese herbal compound for treating or improving anxiety disorder and application thereof, and relates to the technical field of Chinese herbal medicines. According to the traditional Chinese medicine compound, cortex albiziae, longan pulp and citron are used as monarch materials, zedoary, buckeye and scirpus yagara are used as ministers, cortex fraxini, fructus chebulae, cortex dictamni, selfheal, lithospermum and liquorice are used as assistants and guides, all the medicines are combined to regulate qi activity, invigorate qi and blood, dissipate stasis and clear away toxin, and the whole formula has the effects of resolving depression, soothing the nerves, soothing the liver, regulating qi, tonifying heart and spleen, activating blood and clearing heat. The traditional Chinese medicine compound can effectively relieve anxiety mood of a patient, refresh sleep quality and improve anxiety expression such as body symptoms of the patient, is remarkable in curative effect, has huge application potential in the aspect of treating or improving anxiety disorder, and is worthy of popularization.

The present invention relates to pharmaceutical compositions of cannabidiol comprising less than 0.3% of THC for treating various anxiety disorders. The invention also discloses evaluation of efficacy, safety and pharmacokinetics of these compositions for treating mild to moderate anxiety disorders.

This invention relates to the field of medical data processing technology, specifically to a deep learning-based method for predicting adolescent anxiety. The method includes: quantifying gut microbiota characteristics, anxiety behavior characteristics, and environmental stress characteristics; calculating time-series weighting coefficients; integrating gut microbiota characteristics, anxiety behavior characteristics, environmental stress characteristics, and time-series weighting coefficients into a model; and outputting the prediction results. This invention fills the gap in dynamic biomarker modeling in existing anxiety disorder models by integrating research on the human gut microbiota with existing behavioral and environmental factors. Through deep learning, it seeks the long-term relationship between adolescent gut microbiota and anxiety symptoms, addressing the subjectivity, invasiveness, privacy risks, cost, and delays in existing anxiety disorder diagnosis, thus enabling early prevention. It also provides causal evidence for the "gut-brain axis" theory in adolescents, promoting the development of psychomicrobiome research.

The invention discloses a neuron molecular marker for anxiety disorder caused by sibling pressure as well as a screening method and application of the neuron molecular marker, and belongs to the technical field of medical treatment. The molecular marker provided by the invention can be used as a specific diagnosis target of anxiety disorder based on pressure stimulation of the sizer, provides important support for early screening and diagnosis of related anxiety disorder and research and development of treatment drugs, and has the advantages of high specificity, wide application prospect and the like.

The invention relates to an application of an ROS (reactive oxygen species) response type multifunctional nano-delivery drug in preparation of a drug for treating anxiety disorder related to high myopia or high myopia, the drug is TK-F-PEI / siR-A, the drug takes ROS response TK-F-PEI as a carrier, a CCL2 nucleic acid aptamer is arranged on the surface of the carrier, and MMP9siRNA is packaged on the core of the carrier. The invention further provides a preparation method of the medicine. The composition can effectively relieve inflammatory response in high myopia, reduce monocyte infiltration to a central nervous system, target local damaged blood eye and blood brain barriers caused by high myopia through CCL2 / ROS double response, promote barrier repair and break vicious circle of inflammation by silencing MMP9 expression, thereby relieving anxiety symptoms of high myopia patients, and improving the treatment effect of the high myopia patients. The living quality of the patient is improved. The pharmaceutical preparation provided by the invention has the advantages of strong pertinence, obvious curative effect, small side effect and the like, provides a new thought and method for treatment of high myopia related complications, and has a wide application prospect.